About Pricing FAQs Blog

Loading clinical trials...

Your health journey, clearly organized.

Find Clinical Trials →

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Back to clinical trial search

WITHDRAWNPhase 1NCT03629015

Safety Study of Stemchymal® in Acute Liver Failure

To investigate the safety of Stemchymal® via intravenous (IV) infusion in acute liver failure (ALF) and acute on chronic liver failure (ACLF) patients.

Lead sponsor: Steminent Biotherapeutics Inc.•1 locations•View source on ClinicalTrials.gov

Clareo plain-language summary

What this study is about

Generating AI summary...

Clareo turns complex medical information into clear understanding you can use.

Bring this clarity to your next appointment.

Keep all your medical notes and next steps in one place.

Sponsors

Lead Sponsor

Steminent Biotherapeutics Inc.

Collaborators

Taipei Veterans General Hospital, Taiwan

Age

20 - 70 years

Sex

ALL

Healthy Volunteers

No

Inclusion Criteria

•1. ALF or ACLF patients.
•2. Subjects are between 20 and 70 years of age.
•3. MELD scores meet 17 ≤ MELD ≤ 26.
•4. Subjects who had completed signing informed consent.

Exclusion Criteria

•1. Subjects who had been enrolled in any other cell therapy within six months.
•2. Females with a positive pregnancy test result.
•3. Subjects have contraindication for liver transplantation.
•4. Subjects with psychiatric illnesses.
•5. Subjects who are diagnosed as active tuberculosis (TB).
•6. Subjects with immunological disorders (e.g. autoimmune hepatitis) or using immunosuppressive drugs (e.g. steroid for immunosuppression) within six months prior to screening visit.
•7. Subjects with unstable illnesses or contraindication for this clinical trial according to investigator's judgment.

Related studies

RECRUITINGPhase 1/2

Treatment With Human Umbilical Cord-derived Mesenchymal Stromal Cells in Systemic Sclerosis

NCT04356287 · Sclerosis, Systemic, Mesenchymal Stem Cells

ALSS - DPMAS and Therapeutic Plasma Exchange (TPE), Its Effect on Primary Coagulation, Inflammation and the Function of Vital Organs in ALF or ACLF

NCT07329036 · Acute Liver Failure

Standard Volume vs. High Volume Plasma Exchange in Pediatric Acute Liver Failure

NCT06831643 · Acute Liver Failure

RECRUITINGPhase 2/3

Insulin Producing Stem Cell Transplantation Clinical Trial in Type 1 Diabetes

NCT06951074 · Stem Cells, Type 1 Diabetes

Fertility Enhancement Through Regenerative Treatment in Ovaries and Testes

NCT06841328 · Gonadal Dysfunction, Gonadal Failure, and more

View all related studies →

Data from ClinicalTrials.govLast updated on ClinicalTrials.gov: October 28, 2022Terms

Trial snapshot

StatusWITHDRAWN

PhasePHASE1

Enrollment—

Start dateOct 2018

Last updatedOct 28, 2022

Condition

Stem Cells Adult Stem Cells Acute Liver Failure Acute-On-Chronic Liver Failure Steminent

Locations shown

Taipei Veterans General Hospital

Taipei

For caregivers

Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: October 28, 2022Data synced to Clareo: May 10, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions